{"id":335096,"date":"2025-10-27T02:15:14","date_gmt":"2025-10-27T02:15:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/335096\/"},"modified":"2025-10-27T02:15:14","modified_gmt":"2025-10-27T02:15:14","slug":"switzerlands-novartis-buying-san-diego-biotech-avidity-in-12-billion-cash-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/335096\/","title":{"rendered":"Switzerland&#8217;s Novartis buying San Diego biotech Avidity in $12 billion cash deal"},"content":{"rendered":"<p><a href=\"https:\/\/i0.wp.com\/timesofsandiego.com\/wp-content\/uploads\/2025\/10\/Novartis.jpg?ssl=1\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" data-recalc-dims=\"1\" decoding=\"async\" width=\"780\" height=\"439\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/10\/Novartis.jpg\" alt=\"Novartis staff outside a company facility\" class=\"wp-image-352330\"  \/><\/a>Novartis staff celebrate the company\u2019s 25 years in San Diego outside the Genomics Institute of the Novartis Research Foundation in Torrey Pines. (Photo courtesy of the company)<\/p>\n<p>Swiss pharmaceutical giant <a href=\"https:\/\/www.novartis.com\/\" target=\"_blank\" rel=\"noopener\">Novartis<\/a> announced Sunday that it will buy San Diego-based <a href=\"https:\/\/www.aviditybiosciences.com\/\" target=\"_blank\" rel=\"noopener\">Avidity Biosciences<\/a> in a $12 billion all-cash deal.<\/p>\n<p>Founded in 2012, Avidity is developing a new class of RNA therapeutics called antibody oligonucleotide conjugates to treat genetic neuromuscular diseases such as Duchenne muscular dystrophy.<\/p>\n<p>\u201cAvidity\u2019s pioneering AOC platform for RNA therapeutics \u200band its late-stage assets bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases,\u201d said Vas Narasimhan, CEO of Novartis. <\/p>\n<p>\u201cThe Avidity team has built robust programs with industry-leading delivery of RNA therapeutics to muscle tissue. We look forward to developing these programs to meaningfully change the trajectory of diseases for patients,\u201d Narasimhan said.<\/p>\n<p>Avidity stockholders will receive $72 per share in cash at closing, representing a premium of 46% over the stock\u2019s closing price on Friday.<\/p>\n<p>Novartis recently celebrated 25 years of operations in the San Diego region, and earlier this year announced plans to open a <a href=\"https:\/\/timesofsandiego.com\/tech\/2025\/04\/11\/swiss-novartis-to-open-san-diego-research-hub\/\" target=\"_blank\" rel=\"noopener\">$1.1 billion global research hub<\/a> here.<\/p>\n<p>READ NEXT\n\t<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis staff celebrate the company\u2019s 25 years in San Diego outside the Genomics Institute of the Novartis Research&hellip;\n","protected":false},"author":3,"featured_media":335097,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5134],"tags":[1675,5229,165908,3653,1582,276,165909,165910,38967,19203,3549,7264,67,586,132,5230,68,2969],"class_list":{"0":"post-335096","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-san-diego","8":"tag-acquisition","9":"tag-america","10":"tag-avidity-biosciences","11":"tag-biotech","12":"tag-ca","13":"tag-california","14":"tag-cash-deal","15":"tag-duchene-muscular-dystrophy","16":"tag-novartis","17":"tag-rna","18":"tag-san-diego","19":"tag-sandiego","20":"tag-united-states","21":"tag-united-states-of-america","22":"tag-unitedstates","23":"tag-unitedstatesofamerica","24":"tag-us","25":"tag-usa"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115443723769037378","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/335096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=335096"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/335096\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/335097"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=335096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=335096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=335096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}